Literature DB >> 15499168

Decreased expression of glucose and peptide transporters in rat remnant kidney.

Nobuhiko Nakamura1, Satohiro Masuda, Kazushige Takahashi, Hideyuki Saito, Masahiro Okuda, Ken-ichi Inui.   

Abstract

The loss of renal mass induces tubular hypertrophy as well as glomerular sclerosis and results in the end stage of renal disease. However, there is little information about adaptation of tubular glucose and peptide reabsorption under conditions of chronic renal failure. In the present study, we performed functional and molecular analyses focused on the tubular reabsorption of filtered glucose and small peptides using 5/6 nephrectomized rats at 16 weeks, as a model of chronic renal failure. Sixteen weeks after 5/6 nephrectomy or sham treatment, the brush-border membranes and total RNA were obtained from the renal cortex to evaluate the uptake of Na(+) gradient-dependent D-glucose and H(+) gradient-dependent glycylsarcosine. The amounts of SGLT and PEPT mRNA levels were quantified by competitive PCR. The urinary glucose/creatinine ratio was markedly higher in nephrectomized rats than in sham-operated controls. Na(+)-dependent glucose uptake by the isolated renal brush-border membrane vesicles was markedly decreased in nephrectomized rats compared with that in sham-operated controls. However, H(+)-dependent peptide transport, another secondary active transport system in the brush-border membranes, was maintained. In addition, kinetic analysis revealed that both SGLT1 (high-affinity type)- and SGLT2 (low-affinity type)-mediated Na(+)/glucose uptake had markedly decreased Vmax values, but not Km values. Furthermore, competitive PCR demonstrated that the mRNA expression levels of SGLT2, PEPT1 and PEPT2, but not SGLT1, were markedly depressed. These findings suggested that loss of SGLT2 during chronic renal failure implies a high risk of renal glucosuria.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15499168     DOI: 10.2133/dmpk.19.41

Source DB:  PubMed          Journal:  Drug Metab Pharmacokinet        ISSN: 1347-4367            Impact factor:   3.614


  10 in total

1.  Modeling oxygen consumption in the proximal tubule: effects of NHE and SGLT2 inhibition.

Authors:  Anita T Layton; Volker Vallon; Aurélie Edwards
Journal:  Am J Physiol Renal Physiol       Date:  2015-04-08

Review 2.  1,5-Anhydroglucitol in diabetes mellitus.

Authors:  Won Jun Kim; Cheol-Young Park
Journal:  Endocrine       Date:  2012-07-31       Impact factor: 3.633

3.  Altered pharmacokinetics of enrofloxacin in experimental models of hepatic and renal impairment.

Authors:  Y H Hwang; M S Kim; I B Song; J H Lim; B K Park; H I Yun
Journal:  Vet Res Commun       Date:  2008-12-16       Impact factor: 2.459

Review 4.  Proton-coupled oligopeptide transporter family SLC15: physiological, pharmacological and pathological implications.

Authors:  David E Smith; Benjamin Clémençon; Matthias A Hediger
Journal:  Mol Aspects Med       Date:  2013 Apr-Jun

5.  SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy.

Authors:  Paola Cassis; Monica Locatelli; Domenico Cerullo; Daniela Corna; Simona Buelli; Cristina Zanchi; Sebastian Villa; Marina Morigi; Giuseppe Remuzzi; Ariela Benigni; Carlamaria Zoja
Journal:  JCI Insight       Date:  2018-08-09

6.  Effects of renal impairment on transporter-mediated renal reabsorption of drugs and renal drug-drug interactions: A simulation-based study.

Authors:  Kristin E Follman; Rutwij A Dave; Marilyn E Morris
Journal:  Biopharm Drug Dispos       Date:  2018-04       Impact factor: 1.627

7.  Serum 1,5-anhydroglucitol concentrations are a reliable index of glycemic control in type 2 diabetes with mild or moderate renal dysfunction.

Authors:  Won Jun Kim; Cheol-Young Park; Kyu-Beck Lee; Se Eun Park; Eun Jung Rhee; Won Young Lee; Ki Won Oh; Sung Woo Park
Journal:  Diabetes Care       Date:  2011-12-30       Impact factor: 19.112

Review 8.  Sodium-glucose linked transporter-2 inhibitors in chronic kidney disease.

Authors:  L Zanoli; A Granata; P Lentini; S Rastelli; P Fatuzzo; F Rapisarda; P Castellino
Journal:  ScientificWorldJournal       Date:  2015-02-15

9.  The gut microbe Bacteroides fragilis ameliorates renal fibrosis in mice.

Authors:  Wei Zhou; Wen-Hui Wu; Zi-Lin Si; Hui-Ling Liu; Hanyu Wang; Hong Jiang; Ya-Fang Liu; Raphael N Alolga; Cheng Chen; Shi-Jia Liu; Xue-Yan Bian; Jin-Jun Shan; Jing Li; Ning-Hua Tan; Zhi-Hao Zhang
Journal:  Nat Commun       Date:  2022-10-14       Impact factor: 17.694

10.  Pharmacokinetic and pharmacodynamic profiles of canagliflozin in Japanese patients with type 2 diabetes mellitus and moderate renal impairment.

Authors:  Nobuya Inagaki; Kazuoki Kondo; Toru Yoshinari; Manabu Ishii; Masaki Sakai; Hideki Kuki; Kenichi Furihata
Journal:  Clin Drug Investig       Date:  2014-10       Impact factor: 2.859

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.